Abstract
ADP-A2M4CD8 is a next-generation, specific peptide enhanced affinity receptor T-cell therapy modified with addition of a CD8α co-receptor to treat human leukocyte antigen A*02–eligible patients (pts) with unresectable or metastatic tumors positive for the cancer testis antigen melanoma-associated antigen A4 (MAGE-A4). ADP-A2M4CD8 has demonstrated promising anti-tumor activity with a favorable benefit to risk profile in the ongoing phase 1 SURPASS trial.1 Here we report updated clinical outcomes with additional pts treated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
